SCHEMBL21595529

SCHEMBL21595529

CSC(=Nc1ccccc1Cl)c1ccncn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 5/20 0.39
HTR3E A5X5Y0 2/20 0.39
HTR3B O95264 2/20 0.39
HTR3A P46098 2/20 0.39
HTR3D Q70Z44 2/20 0.39
HTR3C Q8WXA8 2/20 0.39
NOS3 P29474 2/20 0.38
NOS1 P29475 2/20 0.38
NOS2 P35228 2/20 0.38
P2RX7 Q99572 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
ALDH1A1 P00352 2/20 0.34
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
ALOX12 P18054 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20333652 1.00 GRM4 (0.39) GRM4HTR3EHTR3BHTR3AHTR3D
SCHEMBL20302215 0.84 GRM4 (0.40) GRM4P2RX7CYP19A1
SCHEMBL20302216 0.84 GRM4 (0.40) GRM4P2RX7CYP19A1
SCHEMBL20302205 0.83 P2RX7 (0.33) GRM4P2RX7TBXA2RHSP90AA1HKDC1
SCHEMBL20302204 0.83 P2RX7 (0.33) GRM4P2RX7TBXA2RHSP90AA1HKDC1
SCHEMBL20303182 0.80 HTR3E (0.43) GRM4HTR3EHTR3BHTR3AHTR3D
SCHEMBL20302486 0.80 HTR3E (0.43) GRM4HTR3EHTR3BHTR3AHTR3D
SCHEMBL20302210 0.80 HTR3E (0.43) GRM4HTR3EHTR3BHTR3AHTR3D
SCHEMBL20302209 0.80 HTR3E (0.43) GRM4HTR3EHTR3BHTR3AHTR3D
SCHEMBL9926216 0.80 HTR3E (0.43) GRM4HTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810597-B1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS UNIV OSLO HF (NO) 2025-11-26 EP disclosed
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors OSLO UNIVERSITETSSYKEHUS HF (NO) 2024-03-12 US disclosed
CN-112469714-B 1,2, 4-triazole derivatives as tankyrase inhibitors 奥斯陆大学国家医院 2024-03-01 CN disclosed
EP-3810597-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS Oslo Universitetssykehus HF (NO) 2021-04-28 EP disclosed
WO-2019243822-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS OSLO UNIVERSITETSSYKEHUS HF (NO) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors GBA3, CBR3, TECR GRM4 3410/4885HTR3E 629/4885HTR3B 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.